TACC3 and non-small cell lung carcinoma: Notably, a patient with epidermal growth factor receptor (EGFR)-mutant advanced NSCLC developed an FGFR3-TACC3 fusion following osimertinib treatment and exhibited a partial response with a combined therapy of erdafitinib and osimertinib [38].